Consequences of glycan truncation on Fc structural integrity

References

• Aggarwal S. Targeted cancer therapies. Nat Rev Drug Discov 2010; 9:427 - 8; http://dx.doi.org/10.1038/nrd3186; PMID: 20514063
   PubMed Web of Science ®Google Scholar
• Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21:1 - 7; http://dx.doi.org/10.2165/00063030-200721010-00001; PMID: 17263584
   PubMed Web of Science ®Google Scholar
• Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526:159 - 66; http://dx.doi.org/10.1016/j.abb.2012.03.021; PMID: 22465822
   PubMed Web of Science ®Google Scholar
• Kabat EA, Te Wu T, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Darby (PA); Diane Publishing; 1992.
   Google Scholar
• Raju S. Glycosylation variations with expression systems. Westborough (MA); BioProcess International; 2003:44-53.
   Google Scholar
• Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10:477 - 86; http://dx.doi.org/10.1093/glycob/10.5.477; PMID: 10764836
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226 - 34; http://dx.doi.org/10.1038/nrd2804; PMID: 19247305
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471 - 8; http://dx.doi.org/10.1016/j.coi.2008.06.007; PMID: 18606225
   PubMed Web of Science ®Google Scholar
• Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311 - 8; http://dx.doi.org/10.1016/0161-5890(95)00118-2; PMID: 8643100
   PubMed Web of Science ®Google Scholar
• Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644 - 52; http://dx.doi.org/10.1021/bp050228w; PMID: 16321047
   PubMed Web of Science ®Google Scholar
• Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 2007; 368:767 - 79; http://dx.doi.org/10.1016/j.jmb.2007.02.034; PMID: 17368483
   PubMed Web of Science ®Google Scholar
• Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 2013; http://dx.doi.org/10.1016/j.ymeth.2013.06.036; PMID: 23851282
   PubMed Web of Science ®Google Scholar
• Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, Heck AJ, Parren PW. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs 2013; 5:219 - 28; http://dx.doi.org/10.4161/mabs.23532; PMID: 23406897
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419 - 25; http://dx.doi.org/10.4161/mabs.20996; PMID: 22699226
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415 - 6; http://dx.doi.org/10.4161/mabs.3.5.17334; PMID: 21785279
   PubMed Web of Science ®Google Scholar
• Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs 2013; 5; http://dx.doi.org/10.4161/mabs.25423; PMID: 23924801
   PubMed Web of Science ®Google Scholar
• Burnina I, Hoyt E, Lynaugh H, Li H, Gong B. A cost-effective plate-based sample preparation for antibody N-glycan analysis. J Chromatogr A 2013; 1307:201 - 6; http://dx.doi.org/10.1016/j.chroma.2013.07.104; PMID: 23932029
   PubMed Web of Science ®Google Scholar
• Stöckmann H, Adamczyk B, Hayes J, Rudd PM. Automated, high-throughput IgG-antibody glycoprofiling platform. Anal Chem 2013; http://dx.doi.org/10.1021/ac402068r; PMID: 23919734
   PubMed Web of Science ®Google Scholar
• Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000; 37:697 - 706; http://dx.doi.org/10.1016/S0161-5890(00)00105-X; PMID: 11275255
   PubMed Web of Science ®Google Scholar
• Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011; 3:568 - 76; http://dx.doi.org/10.4161/mabs.3.6.17922; PMID: 22123061
   PubMed Web of Science ®Google Scholar
• Latypov RF, Hogan S, Lau H, Gadgil H, Liu D. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 2012; 287:1381 - 96; http://dx.doi.org/10.1074/jbc.M111.297697; PMID: 22084250
   PubMed Web of Science ®Google Scholar
• Solá RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009; 98:1223 - 45; http://dx.doi.org/10.1002/jps.21504; PMID: 18661536
   PubMed Web of Science ®Google Scholar
• Rhodes G. Crystallography made crystal clear: a guide for users of macromolecular models. Philadelphia (PA); Elsevier Academic Press; 2010.
   Google Scholar
• Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR. Characterization of IgG1 Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry. Anal Chem 2009; 81:5966; http://dx.doi.org/10.1021/ac9009287; PMID: 19606834
   PubMed Web of Science ®Google Scholar
• Caflisch A. Computational models for the prediction of polypeptide aggregation propensity. Curr Opin Chem Biol 2006; 10:437 - 44; http://dx.doi.org/10.1016/j.cbpa.2006.07.009; PMID: 16880001
   PubMed Web of Science ®Google Scholar
• Chaudhri A, Zarraga IE, Yadav S, Patapoff TW, Shire SJ, Voth GA. The role of amino acid sequence in the self-association of therapeutic monoclonal antibodies: insights from coarse-grained modeling. J Phys Chem B 2013; 117:1269 - 79; http://dx.doi.org/10.1021/jp3108396; PMID: 23316912
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 2010; 114:6614 - 24; http://dx.doi.org/10.1021/jp911706q; PMID: 20411962
   PubMed Web of Science ®Google Scholar
• Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, Zhang H, Fritsch C, Heine H, Trout BL. Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PLoS One 2009; 4:e8425; http://dx.doi.org/10.1371/journal.pone.0008425; PMID: 20037630
   PubMedGoogle Scholar
• Wu C, Shea JE. Coarse-grained models for protein aggregation. Curr Opin Struct Biol 2011; 21:209 - 20; http://dx.doi.org/10.1016/j.sbi.2011.02.002; PMID: 21371882
   PubMed Web of Science ®Google Scholar
• Wang X, Kumar S, Buck PM, Singh SK. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations. Proteins 2013; 81:443 - 60; http://dx.doi.org/10.1002/prot.24202; PMID: 23065923
   PubMed Web of Science ®Google Scholar
• Buck PM, Kumar S, Singh SK. Insights into the potential aggregation liabilities of the b12 Fab fragment via elevated temperature molecular dynamics. Protein Eng Des Sel 2013; 26:195 - 205; http://dx.doi.org/10.1093/protein/gzs099; PMID: 23188804
   PubMed Web of Science ®Google Scholar
• Wang X, Kumar S, Singh SK. Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations. Pharm Res 2011; 28:3128 - 44; http://dx.doi.org/10.1007/s11095-011-0503-9; PMID: 21671135
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, Kato K. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta 2006; 1760:693 - 700; http://dx.doi.org/10.1016/j.bbagen.2005.10.002; PMID: 16343775
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981; 20:2361 - 70; http://dx.doi.org/10.1021/bi00512a001; PMID: 7236608
   PubMed Web of Science ®Google Scholar
• Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979 - 89; http://dx.doi.org/10.1016/S0022-2836(02)01250-0; PMID: 12527303
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715 - 25; http://dx.doi.org/10.1038/nri2155; PMID: 17703228
   PubMed Web of Science ®Google Scholar
• Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010; 30:Suppl 1 S9 - 14; http://dx.doi.org/10.1007/s10875-010-9405-6; PMID: 20480216
   PubMedGoogle Scholar
• Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373 - 6; http://dx.doi.org/10.1126/science.1154315; PMID: 18420934
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203:789 - 97; http://dx.doi.org/10.1084/jem.20051900; PMID: 16520389
   PubMed Web of Science ®Google Scholar
• Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A 2013; 110:9868 - 72; http://dx.doi.org/10.1073/pnas.1307864110; PMID: 23697368
   PubMed Web of Science ®Google Scholar
• Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36:1370 - 80; http://dx.doi.org/10.1021/bi9621472; PMID: 9063885
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Kato K, Shindo M, Aoki S, Furusho K, Koga K, Takahashi N, Arata Y, Shimada I. Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. J Biomol NMR 1998; 12:385 - 94; http://dx.doi.org/10.1023/A:1008392229694; PMID: 9835046
   PubMed Web of Science ®Google Scholar
• Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 2012; 51:4618 - 26; http://dx.doi.org/10.1021/bi300319q; PMID: 22574931
   PubMed Web of Science ®Google Scholar
• Barb AW, Prestegard JH. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol 2011; 7:147 - 53; http://dx.doi.org/10.1038/nchembio.511; PMID: 21258329
   PubMed Web of Science ®Google Scholar
• Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267 - 73; http://dx.doi.org/10.1038/35018508; PMID: 10917521
   PubMed Web of Science ®Google Scholar
• Deisenhofer J, Colman PM, Huber R, Haupt H, Schwick G. Crystallographic structural studies of a human Fc-fragment. I. An electron-density map at 4 A resolution and a partial model. Hoppe Seylers Z Physiol Chem 1976; 357:435 - 45; http://dx.doi.org/10.1515/bchm2.1976.357.1.435; PMID: 955567
   PubMedGoogle Scholar
• Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm W. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 1976; 264:415 - 20; http://dx.doi.org/10.1038/264415a0; PMID: 1004567
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001; 293:1155 - 9; http://dx.doi.org/10.1126/science.1061692; PMID: 11498595
   PubMed Web of Science ®Google Scholar
• Perez D, Uberuaga BP, Voter AF. Accelerated Molecular Dynamics Methods. Hierarchical Methods for Dynamics in Complex Molecular Systems 2012; 10:329
   Google Scholar
• Caflisch A, Karplus M. Molecular dynamics simulation of protein denaturation: solvation of the hydrophobic cores and secondary structure of barnase. Proc Natl Acad Sci U S A 1994; 91:1746 - 50; http://dx.doi.org/10.1073/pnas.91.5.1746; PMID: 8127876
   PubMed Web of Science ®Google Scholar
• Caflisch A, Karplus M. Acid and thermal denaturation of barnase investigated by molecular dynamics simulations. J Mol Biol 1995; 252:672 - 708; http://dx.doi.org/10.1006/jmbi.1995.0528; PMID: 7563082
   PubMed Web of Science ®Google Scholar
• Li A, Daggett V. Identification and characterization of the unfolding transition state of chymotrypsin inhibitor 2 by molecular dynamics simulations. J Mol Biol 1996; 257:412 - 29; http://dx.doi.org/10.1006/jmbi.1996.0172; PMID: 8609633
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2011.
   Google Scholar
• Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26:1781 - 802; http://dx.doi.org/10.1002/jcc.20289; PMID: 16222654
   PubMed Web of Science ®Google Scholar
• Wang J, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J Comput Chem 2000; 21:1049 - 74; http://dx.doi.org/10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Web of Science ®Google Scholar
• Kirschner KN, Yongye AB, Tschampel SM, González-Outeiriño J, Daniels CR, Foley BL, Woods RJ. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem 2008; 29:622 - 55; http://dx.doi.org/10.1002/jcc.20820; PMID: 17849372
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33 - 8, 27-8; http://dx.doi.org/10.1016/0263-7855(96)00018-5; PMID: 8744570
   PubMed Web of Science ®Google Scholar
• Cross S, Kuttel MM, Stone JE, Gain JE. Visualisation of cyclic and multi-branched molecules with VMD. J Mol Graph Model 2009; 28:131 - 9; http://dx.doi.org/10.1016/j.jmgm.2009.04.010; PMID: 19473861
   PubMedGoogle Scholar